Switching From Semaglutide to Tirzepatide: What Changes and Who Decides

Yes, you can switch from semaglutide to tirzepatide, and the decision belongs to a licensed physician. The two molecules act on different receptors: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GIP and GLP-1 receptors. There is no dose conversion chart in the approved labeling. Tirzepatide is started at its own labeled starting dose regardless of the semaglutide dose you were on, and the physician adjusts it from there. Compounded versions of either molecule are not FDA-approved as final products.

This guide is for the patient on semaglutide who is wondering about tirzepatide: why people switch, what is actually different, why "dose conversion" is the wrong question, how a physician manages the change, what it costs, and what to ask. Medication is prescribed only if a licensed physician determines it is appropriate. Do not stop or change any medication on your own.

Why people consider switching from semaglutide to tirzepatide

Switching between the two molecules is a recognized clinical scenario. A 2026 article in The Pharmaceutical Journal, a UK pharmacy publication, lists what leads clinicians to consider a switch between these agents: adverse effects, patient preference, cost pressures and formulary decisions. In a patient's words, the reasons sound like this:

• Side effects that have not settled. Nausea, vomiting, diarrhea, constipation and abdominal pain are among the most common adverse reactions in the approved semaglutide labeling. When they persist after the physician has already adjusted dose and timing, a different molecule is one option the physician may raise.
• A plateau after the adjustments have been made. Whether a stall on semaglutide is a reason to switch is a clinical judgement that depends on what has already been tried, and no one can promise that a different molecule will change it.
• Availability and cost. Pharmacy options and monthly price can differ between the two molecules and between approved and compounded forms.
• A physician's recommendation. Sometimes the idea comes from the prescriber, based on your history and how you have responded.

None of these is a promise about outcomes. They are reasons to open a conversation with the physician.

What is actually different between semaglutide and tirzepatide

The receptors. According to the prescribing information on DailyMed, the National Library of Medicine's label database, semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. Tirzepatide is a GIP receptor and GLP-1 receptor agonist: it activates both the GIP and GLP-1 receptors. Both labels describe GLP-1 as a physiological regulator of appetite and caloric intake. The two molecules share one target and differ by one.

The form. The approved injectable forms of both molecules are given once weekly by subcutaneous injection. Semaglutide is also approved as a once-daily tablet; the approved tirzepatide products are injections.

One class boxed warning, the same contraindications. Both approved products carry a boxed warning that, in rodents, the drug causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors, and that it is unknown whether the product causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Both are contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and after a serious hypersensitivity reaction to the molecule or its excipients. The physician will ask those screening questions again.

The warnings overlap. Both labels list acute pancreatitis, acute gallbladder disease, severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion and hypersensitivity reactions among their warnings and precautions.

Neither is taken with the other. The tirzepatide label says coadministration with any GLP-1 receptor agonist is not recommended, and the semaglutide label carries the mirror sentence. A switch is a switch, not an overlap.

A head-to-head trial of the approved products exists. Aronne and colleagues published a comparison of tirzepatide and semaglutide for the treatment of obesity in the New England Journal of Medicine in 2025; the citation is in the sources below. We do not summarize its results: what a trial average means for you is a conversation for your physician, and comparative claims about one molecule over the other are not ours to make.

Is there a semaglutide to tirzepatide conversion chart?

No. The honest answer is short.

The prescribing information for the approved tirzepatide products gives one recommended starting dosage for all indications. The label states that this starting dosage is for treatment initiation and is not approved as a maintenance dosage, that the dosage is then increased stepwise, and that the escalation schedule exists to reduce the risk of gastrointestinal adverse reactions. The prescriber is told to consider treatment response and tolerability when selecting the maintenance dosage, and a lower maintenance dosage may be considered if a higher one is not tolerated.

What the label does not contain is any table, sentence or footnote mapping semaglutide doses to tirzepatide doses, and it does not address switching from semaglutide at all. The Pharmaceutical Journal puts the pharmacology in one line: there is no validated dose equivalence between the two agents owing to their differing receptor profiles.

In practice, tirzepatide after semaglutide starts at its own labeled starting dose: the semaglutide dose you are on today does not determine it, and the physician decides each step based on how you respond and tolerate it. A small retrospective report in patients with type 2 diabetes, published in 2025, describes this pattern: tirzepatide was started at its labeled starting dose after semaglutide and escalated stepwise, with further escalation decided on clinical judgment. We cite it for the pattern, not for its outcomes, which come from a small diabetes cohort and do not transfer to you.

A "conversion chart" on a forum or a clinic website is opinion, not labeling. The FDA has received adverse event reports that may relate to compounded semaglutide and tirzepatide used in doses beyond the approved label, including increasing the amount more quickly than the label's schedule. The physician sets the starting dose and the steps for a reason.

How a switch from semaglutide to tirzepatide works in practice

From the patient's side, a well-run switch looks like this.

1. The physician reviews where you are. Your current semaglutide dose, how long you have been on it, which side effects you have had and how they were managed, your medical history (including the thyroid, pancreatitis and gallbladder history the labels ask about), other medications, and what you hope to change.
2. The physician decides whether tirzepatide is appropriate. That includes whether tirzepatide is appropriate for you at all and, if a compounded preparation is being considered, whether the compounded preparation is appropriate for you specifically. The answer can be no, or not yet.
3. The physician sets the timing. The approved tirzepatide labeling does not address switching from semaglutide and sets no waiting period between the last dose of one and the first dose of the other. The two are not taken together, and the interval is set by the physician for you. Do not decide it on your own.
4. Tirzepatide starts at its labeled starting dose. Not at a dose matched to your semaglutide dose, because no such equivalence exists in the labeling. From there the physician adjusts stepwise, watching response and tolerability.
5. You watch the first stretch on the new molecule. The most common adverse reactions in the tirzepatide label are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain and dyspepsia. The label also notes that reported acute kidney injury occurred mostly in patients whose gastrointestinal reactions led to dehydration, with renal function to be monitored especially during dose initiation and escalation. Keep fluids up, and tell the physician early if you cannot keep them down.
6. You know when to call. MedlinePlus, the National Library of Medicine's patient drug information, gives the plain-language rule for tirzepatide: tell your doctor if nausea, vomiting, diarrhea, decreased appetite, constipation or upset stomach are severe or do not go away; stop taking tirzepatide and call your doctor immediately for stomach pain that will not go away and may radiate to the back, or for swelling of the face, throat or mouth, hives, rash, trouble swallowing or breathing, dizziness or a rapid heartbeat.

For two common side-effect questions, we have separate guides on tirzepatide and constipation and on whether tirzepatide makes you tired.

Switching from tirzepatide to semaglutide: the other direction

The switch runs the other way too, and the same rules apply. A patient on tirzepatide may ask about semaglutide because side effects have not settled after the physician's adjustments, because of cost or availability, or because the prescriber raises it. As with the forward switch, none of these is a promise about outcomes, and the decision belongs to a licensed physician who has reviewed the file.

There is no conversion chart in this direction either. The approved semaglutide labeling does not address switching from tirzepatide and sets no waiting period after it; it gives its own recommended starting dosage and its own stepwise escalation schedule. So semaglutide after tirzepatide starts at its own labeled starting dose, not at a dose matched to the tirzepatide dose you were on, and the physician sets each step and the timing of the last tirzepatide dose and the first semaglutide dose. The two molecules are not taken together.

Expect the same screening questions about thyroid, pancreatitis and gallbladder history, because both labels carry the same class boxed warning, the same contraindications and overlapping warnings, and expect the physician to watch the first stretch on semaglutide for the reactions its label lists among the most common: nausea, diarrhea, vomiting, constipation and abdominal pain. If you are a Majesta Health patient on Performance, the same message to your physician starts the conversation; if semaglutide is prescribed, your plan changes to Essential from the next cycle, and you see the new price before you are charged.

Switching between compounded and FDA-approved forms

This article describes a change of molecule. A change of source, from an FDA-approved product to a compounded preparation or the other way round, is a different question, covered in our hubs on compounded semaglutide and compounded tirzepatide. Three facts apply whichever way you move:

• Compounded tirzepatide is prepared by a state-licensed 503A pharmacy on a patient-specific prescription. Under section 503A of the federal Food, Drug, and Cosmetic Act, the drug is compounded for an identified individual patient based on a valid prescription order, and the FDA says state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies.
• Compounded medications are not FDA-approved as final products. In the FDA's words, the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. The FDA lists, among its telehealth red flags, a company that claims a compounded drug is the same as an FDA-approved drug. We do not make that claim; walk away from any provider that does.
• The FDA's stated position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. That is one more reason the decision sits with a licensed physician who has reviewed your file, not with a website.

How the telehealth route itself works, and how to tell a legitimate source from an illegal one, is covered in how to get tirzepatide.

What switching costs at Majesta Health

At Majesta Health the two molecules are two plans:

• Essential (compounded semaglutide injection): $179 your first month, then $299 every 30 days.
• Performance (compounded tirzepatide injection): $339 your first month, then $439 every 30 days.

Both include the physician review (a $20 medical consultation fee is included in the first-month price), the medication, shipping and ongoing physician messaging. Nothing is charged at checkout: the first-month price is charged only after a licensed physician reviews your file and approves treatment. If treatment is not approved, you are not charged.

For an existing Majesta patient, a switch is a change of plan: if the physician prescribes tirzepatide, the plan and price change to Performance from the next cycle, and you see the new price before you are charged. We keep other providers' prices off this page; to compare the market, our compounded tirzepatide cost guide and compounded semaglutide cost guide break down what a monthly figure should include. Full plan details are on the pricing page.

Questions to bring to the physician

• Based on what I have told you about side effects and progress, is a switch worth considering, or is there an adjustment on semaglutide we have not tried?
• Given my history, is tirzepatide appropriate for me, and is the compounded preparation appropriate for me specifically?
• What is my starting dose, and how will you decide each step after that?
• When do I take my last semaglutide dose, and when do I take my first tirzepatide dose?
• Which side effects should I expect, and what should make me contact you the same day?
• If tirzepatide does not suit me, can I go back to semaglutide?
• What changes on my plan and my monthly price, and when?

How it works at Majesta Health

If you are already a Majesta Health patient on Essential and want to discuss a switch, message your physician from your patient account. The physician reviews your history, side effects and goals and decides whether tirzepatide is appropriate for you. If tirzepatide is prescribed, your plan and price change to Performance from the next cycle, and you see the new price before you are charged.

If you are not yet a patient and are on semaglutide from another source, the 2-minute medical assessment is where the conversation starts: you tell us what you are taking now, a physician licensed in your state reviews your file, and nothing is charged unless a physician approves treatment. Our state availability pages list the current status for each state. Medication is prescribed only if a licensed physician determines it is appropriate. Compounded medications are not FDA-approved as final products.

The bottom line

Switching from semaglutide to tirzepatide is a real option and a physician's decision. The molecules differ in receptor targets, share a class boxed warning and the same thyroid contraindications, and are not taken together. There is no conversion chart in the labeling: tirzepatide starts at its own labeled starting dose, and the physician sets each step and the timing. Compounded versions of both are not FDA-approved as final products. Individual results may vary. Do not stop or change any medication on your own; bring the questions above to your physician instead.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate. Prices are Majesta Health's published prices as of September 2026 and are subject to change. Individual results may vary. Do not stop or change any medication on your own.